Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by bassinion Oct 13, 2020 4:39pm

259 Views

Post# 31708880

Theratechnologies Confirms Issuance Of U.S. Patent Covering

Montral, Canada – Le 13 octobre 2020 –Theratechnologies inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), une socit biopharmaceutique commerciale axe sur le dveloppement et la commercialisation de traitements innovateurs, a le plaisir d’annoncer que le United States Patent and Trademark Office (USPTO) a mis le brevet amricain n. 10,799,562 portant sur le traitement de la statohpatite non alcoolique (NASH) et/ou la statose hpatique (NAFLD) chez les patients utilisant la tsamorline.

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide